Peer-reviewed article
DIPG-44. A GAIN OF FUNCTION Ezh2 MUTATION DELAYS DIFFUSE INTRINSIC PONTINE GLIOMA PROGRESSION
Dhar S, Gadd S, Brat D, Becher O ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a basic science research paper investigating the role of the Ezh2 gene in diffuse intrinsic pontine glioma (DIPG), a fatal pediatric brain cancer. The study used genetically modified mice to test whether increased Ezh2 activity affects tumor progression. Results showed a modest survival advantage and changes in tumor markers, but this is fundamental laboratory research, not an evaluation of an intervention for children's well-being.
Key points
- Enhanced Ezh2 activity delayed DIPG progression by approximately 10 days in mouse models
- Tumors with Ezh2 overexpression showed higher H3K27me3 levels and lower proliferation markers
- Gene expression analysis revealed suppression of inflammatory and interferon pathways in the Ezh2 overexpression group
- This is exploratory basic science research in animal models, not a clinical trial or intervention study
Limitations
This is fundamental laboratory research conducted in genetically modified mice and does not include any human subjects, clinical trials, or evaluation of real-world interventions. The findings cannot directly inform policy or practice for children with DIPG without substantial further translational and clinical research.
Abstract
Abstract BACKGROUND Diffuse Intrinsic Pontine Glioma (DIPG) remains an incurable pediatric brain cancer. The oncohistone H3K27M implicated in 80% of the cases, is also predicted to target Enhancer of Zeste Homolog 2 (Ezh2), the catalytic component of the Polycomb Repressor Complex 2 (PRC2). There are no reported mutations of Ezh2 and its function in DIPG is not fully determined. This work aims to address the role of Ezh2 in DIPG. METHODS Brainstem tumors were established by intracranial injections of Nestin;Tv-a; Ezh2Y641F/+ (NTv-a; Ezh2Y641F/+) neonatal pups using Replication Competent Avian Sarcoma leucosis virus long terminal repeat with splice acceptor (RCAS) viruses, expressing PDGF-B, p53 shRNA, and RCAS-CRE/Y. Immunohistochemical staining for Ki-67 and H3K27me3 were performed on the Discovery ULTRA (Ventana). RESULTS Ezh2 overexpression (Ezh2Y641F/+, RCAS CRE) conferred a survival advantage of approximately 10 days (n=20 mice/group, p<0.001). H3K27me3 levels were significantly upregulated in RCAS CRE group (50% vs 20% in RCAS Y, n=4 tumors/group, p<0.03), with a concomitant lower Ki-67 staining (30% vs. 55% in RCAS Y, n=3 tumors/group, p<0.05). Interestingly, pathological review categorized more RCAS-CRE tumors as ‘atypical’. RNA-sequencing of virus-infected neural precursor cells revealed a suppression of inflammatory/interferon gene signature in the Ezh2 overexpression group. CONCLUSIONS AND FUTURE DIRECTIONS: Enhanced Ezh2 activity appears to delay DIPG pathogenesis. Ongoing work aims to highlight the contribution of differentially expressed gene signatures that contribute to this phenotype.